Versant Venture Management, LLC

In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 8, 2024), Versant Venture Management, LLC reported 6 stock positions worth $63.6 million. Its top holding was Crispr Therapeutics (CRSP) at 36.8% of the portfolio, followed by Contineum Therapeutics Class A (CTNM, 27.6%) and Repare Therapeutics (RPTX, 14.3%). Compared with Q2 2024, it sold out of 2. The biggest sale was an exit from Passage Bio (PASG).

Most Recent 13F
Q2 2026
Location
San Francisco, CA
CIK
0001560009
Portfolio Value
$63.6M (Q3 2024)
SEC Filing
0000950123-24-010733 ↗ filed Nov 8, 2024

Holdings Value

0$50.0M$100.0M$150.0M$200.0M$250.0M Q1 2024: $103.1M Q1 2024 Q2 2024: $77.3M Q2 2024 Q3 2024: $63.6M $63.6M Q3 2024 Q4 2024: $86.7M Q4 2024 Q1 2025: $60.2M Q1 2025 Q2 2025: $82.1M Q2 2025 Q3 2025: $212.5M Q3 2025 Q4 2025: $151.1M Q4 2025 Q1 2026: $141.4M Q1 2026 Q2 2026: $162.6M Q2 2026

Holdings 6 stocks · $63.6M
CRSP Crispr Therapeutics AG 36.84% 498,558 $23.4M No change
CTNM Contineum Therapeutics Inc. Class A 27.64% 918,163 $17.6M No change
RPTX Repare Therapeutics Inc. 14.32% 2,646,657 $9.1M No change
SKYE Skye Bioscience Inc. 12.35% 2,007,704 $7.9M No change
ADVM Adverum Biotechnologies Inc. 5.60% 506,821 $3.6M No change
GRITSTONE BIO INC 3.25% 3,561,150 $2.1M No change

Portfolio Sells Q2 2024 → Q3 2024
PASG Passage Bio Inc. Sold out 0.00% −4.14
ALGS Aligos Therapeutics Inc. Sold out 0.00% −0.66

Portfolio Buys Q2 2024 → Q3 2024
None this quarter.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 8$162.6MGLUE, IPSC, JBIO, LENZ, CTNM
Q1 2026 8$141.4MGLUE, IPSC, LENZ, JBIO, CTNM
Q4 2025 7$151.1MGLUE, LENZ, JBIO, CRSP, CTNM
Q3 2025 9$212.5MLENZ, GLUE, JBIO, CRSP, SKYE
Q2 2025 8$82.1MGLUE, CRSP, JBIO, SKYE, RPTX
Q1 2025 7$60.2MGLUE, CRSP, CTNM, SKYE, RPTX
Q4 2024 7$86.7MGLUE, CRSP, CTNM, SKYE, RPTX
Q3 2024 6$63.6MCRSP, CTNM, RPTX, SKYE, ADVM
Q2 2024 8$77.3MCRSP, CTNM, SKYE, RPTX, ADVM
Q1 2024 7$103.1MCRSP, SKYE, RPTX, GRITSTONE BIO INC, ADVM